Biosergen AB: Flerie publishes merger document
On 26 June 2026, Biosergen AB ("Biosergen") announced that the Boards of Directors of Flerie AB (publ) ("Flerie") and Biosergen jointly have adopted a merger plan through a merger in which Biosergen will be absorbed by Flerie (the "Merger"). Following the completion of the Merger, Biosergen's operations will be contributed to a new subsidiary of Flerie's wholly owned subsidiary, Flerie Invest AB.
THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR SOUTH AFRICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH LAW.
Today, Flerie publishes a merger document regarding the Merger with Biosergen in accordance with the Stock Market Self-Regulation Committee's (Sw. Aktiemarknadens självregleringskommittés) Takeover Rules for certain trading platforms. The merger document is published and made available on the respective websites of Flerie and Biosergen, www.flerie.com and www.biosergen.net. The merger document has not been reviewed or approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen).
An Extraordinary General Meeting in Flerie to approve the merger plan and the issue of the merger consideration will be held on 6 August 2026. An Extraordinary General Meeting in Biosergen to approve, among other things, the merger plan will be held on 6 August 2026.
Advisors
Flerie has retained Setterwalls Advokatbyrå AB as legal advisor and Bergs Securities AB as issuing agent. Biosergen has engaged BAHR as legal advisor.
For further information, please contact:
Tine Kold Olesen, CEO
E-mail: [email protected]
Phone: +45 3135 5707
Mark Beveridge, CFO
E-mail: [email protected]
Phone: +46 76 805 8288
The information was submitted for publication, by the agency of the contact persons above, on 16 July 2026.
The Company's Certified Adviser is Carnegie Investment Bank AB (publ).
About Biosergen
Biosergen is a clinical-stage biotechnology company in the therapeutic area of life-threatening fungal diseases. Biosergen aims to develop the drug candidate BSG005, including new formulations, into a new first-line treatment for resistant and/or difficult-to-treat invasive fungal infections. The company strives to set a new standard for combating these infections where current treatments fall short, thereby saving thousands of lives each year among cancer patients with compromised immune systems, transplant recipients and AIDS patients.
Important Information
In the information below, "this press release" refers to this document, its content or part thereof, oral presentations, Q&A sessions and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an Extraordinary General Meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an inducement to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction's securities law. Decisions regarding the proposed legal Merger between Flerie and Biosergen shall be made solely on the basis of information stated in the actual notices to attend Flerie's and Biosergen's Extraordinary General Meetings, as applicable, and the merger document relating to the Merger, and to independent analyses of the information therein. You should read the merger document, which will be available before the Extraordinary General Meetings which will decide on the issues set forth herein, to obtain more complete information on the Merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision.
This press release contains forward-looking information. Forward-looking information is inherently associated with known and unknown risks, uncertainties, assumptions and other factors, as it relates to circumstances and depends on circumstances that occur in the future, whether within or outside the respective companies' control. Such factors may cause actual results, performance and actual development to deviate significantly from what is expressed or implied in the forward-looking information. Although each company's management believes that their expectations stated in the forward-looking information are reasonable based on such information that is available to them, no guarantee is given that such forward-looking information will prove to be accurate. Undue weight should not be given to forward-looking information. The forward-looking information applies only to the day of this press release and neither Flerie nor Biosergen undertake any obligation to update the forward-looking information beyond what is required pursuant to applicable law. Flerie's and Biosergen's past performance does not guarantee, nor does it represent, the future performance of Flerie. Furthermore, Flerie, Biosergen and their respective subsidiaries, senior executives, employees and agents undertake no obligation to review, update or confirm expectations or estimates, or revise forward-looking information to reflect events that occur, or circumstances that arise, in relation to the content of the press release. Furthermore, it is not certain that the Merger will be carried out in the manner and within the time frame described in this press release or at all.